Exelixis, Inc. (EXEL) |
23.67 0.38 (1.63%) 04-24 13:04 |
Open: | 23.2 |
High: | 23.685 |
Low: | 23.19 |
Volume: | 636,988 |
Market Cap: | 6,978(M) |
PE Ratio: | 36.42 |
Exchange: | NASDAQ Global Select |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 28.11 |
Resistance 1: | 24.07 |
Pivot price: | 23.07 |
Support 1: | 22.93 |
Support 2: | 22.23 |
52w High: | 24.34 |
52w Low: | 18.08 |
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
EPS | 0.650 |
Book Value | 7.480 |
PEG Ratio | 0.95 |
Gross Profit | 0.000 |
Profit Margin (%) | 11.35 |
Operating Margin (%) | 17.05 |
Return on Assets (ttm) | 3.5 |
Return on Equity (ttm) | 8.7 |
Mon, 22 Apr 2024
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors - Simply Wall St
Mon, 22 Apr 2024
Calamos Advisors LLC Acquires New Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Wed, 17 Apr 2024
Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term ... - Yahoo Finance
Thu, 11 Apr 2024
Exelixis stock slips as Barclays downgrades (NASDAQ:EXEL) - Seeking Alpha
Thu, 04 Apr 2024
Exelixis, Inc.'s (NASDAQ:EXEL) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - Simply Wall St
Thu, 21 Mar 2024
Exelixis, Inc.'s (NASDAQ:EXEL) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |